Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

UBS Just Upgraded Argenx Stock. Here's Why.

Argenx (ARGX) stock pushed higher on Aug. 26 after UBS issued a bullish note in favor of the biotech firm, citing a stronger outlook for its flagship Vyvgart franchise. Analyst Xian Deng upgraded ARGX this morning to “Buy” and raised her price target significantly to $1,400, indicating potential upside of about 37% from current levels.

Note that Argenx shares have already been a blockbuster investment for 2026, currently up more than 50% versus their year-to-date low.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.